Treating laryngopharyngeal reflux: Evaluation of an anti-reflux program with comparison to medications

Yang, Jin Mo; Dehom, Salem; Sanders, Stephanie A.; Murry, Thomas; Krishna, Priya; Crawley, Brianna K.

doi:10.1016/j.amjoto.2017.10.014

Cited by 31 publications

(34 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PPIs have been associated with H 2 R in four studies[28,66,70,72]. In comparison with twice daily PPIs, the use of H 2 R does not make sense regarding their short duration of action (6 to 12 h)[94,95].…”

Section: Discussionmentioning

confidence: 99%

Treatment of laryngopharyngeal reflux disease: A systematic review

Lechien¹,

Mouawad²,

Barillari³

et al. 2019

WJCC

View full text Add to dashboard Cite

BACKGROUNGFor a long time, laryngopharyngeal reflux disease (LPRD) has been treated by proton pump inhibitors (PPIs) with an uncertain success rate.AIMTo shed light the current therapeutic strategies used for LPRD in order to analysis the rationale in the LPRD treatment.METHODSThree authors conducted a PubMed search to identify papers published between January 1990 and February 2019 about the treatment of LPRD. Clinical prospective or retrospective studies had to explore the impact of medical treatment(s) on the clinical presentation of suspected or confirmed LPRD. The criteria for considering studies for the review were based on the population, intervention, comparison, and outcome framework.RESULTSThe search identified 1355 relevant papers, of which 76 studies met the inclusion criteria, accounting for 6457 patients. A total of 64 studies consisted of empirical therapeutic trials and 12 were studies where authors formally identified LPRD with pH-monitoring or multichannel intraluminal impedance-pH monitoring (MII-pH). The main therapeutic scheme consisted of once or twice daily PPIs for a duration ranged from 4 to 24 wk. The most used PPIs were omeprazole, esomeprazole, rabeprazole, lansoprazole and pantoprazole with a success rate ranging from 18% to 87%. Other composite treatments have been prescribed including PPIs, alginate, prokinetics, and H2 Receptor antagonists.CONCLUSIONRegarding the development of MII-pH and the identification of LPRD subtypes (acid, nonacid, mixed), future studies are needed to improve the LPRD treatment considering all subtypes of reflux.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of laryngopharyngeal reflux disease: A systematic review

Lechien¹,

Mouawad²,

Barillari³

et al. 2019

WJCC

View full text Add to dashboard Cite

show abstract

“…It is important to consider that increased amyloid level occurs not only in Alzheimer's disease but also in most cognitive impairment states; we can therefore infer that this problem may be underestimated and wider studies with more complex models are necessary to obtain an understanding of the full scope of the problem [72,73]. PPI alter absorption of certain nutrients such as vitamin B12, Fe and NO [34,71,74]. Vitamin B12 deficiency is an effect of hypochlorhydria, which impairs release of dietary proteinbound vitamin B12 that can be absorbed from the terminal ileum.…”

Section: Metabolic Changesmentioning

confidence: 99%

Possible Effects of Proton Pump Inhibitors on Hearing Loss Development

Wiciński

Malinowski

Puk

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

For their being considered safe and as over-the-counter (OTC) drugs, proton pump inhibitors (PPI) are one of the most frequently used medicines nowadays. However, for the last couple of years, many researches analyzing PPI were conducted and these studies shed light on PPI side effects and mechanisms of these processes. Particularly, interesting is the impact of PPI on hearing loss development. However, this side effect seems to be local and its mechanisms are complex and systemic and involve changes in the whole body. This paper summarizes how through, inter alia, alterations in circulatory system, respiratory system, central nervous system, and metabolic changes PPI can cause hearing impairment, which can occur at every age and is connected with long-term use of this group of drugs. Another important finding is the role of PPI in acceleration of presbycusis development which is disturbing with regard to the fact that elders are the group who most frequently use PPI in the long term. Hearing loss is the factor which gravely decreases life quality, especially among elders who are the most afflicted group; thus, administration of PPI should be considered carefully, taking under consideration all benefits and all potential side effects.

show abstract

“…Some studies demonstrated clinically evident benefits in the treatment but some studies did not report any clinical benefits of the use of H2RA in LPR. [19][20][21][22] There are very few studies that have studied the effects of combination therapy with PPI and H2RA (BBF/HS dose) in patients with LPR. The objective of this study was to evaluate once-daily, 40 mg pantoprazole and once nightly, 300 mg ranitidine (BBF/HS) dosing as an alternative empiric regimen in the management of LPR.…”

Section: Introductionmentioning

confidence: 99%

Combination drug therapy for laryngopharyngeal reflex

Hussain

Makhdoomi

Showkat

2020

Int J Otorhinolaryngol Head Neck Surg

View full text Add to dashboard Cite

Background: We sought to evaluate the combination of high-dose prebreakfast proton pump inhibitors (PPIs) (40 mg pantoprazole) and a bedtime high-dose ranitidine (300 mg) dosing as a surrogate and rational regimen for LPR.Methods: 60 subjects that presented to ENT and HNS OPD with symptoms of laryngopharyngeal reflux (LPR) were prospectively evaluated and underwent a comprehensive otolaryngological examination. All subjects were treated sequentially and outcomes recorded using reflux finding score (RFS) and reflux symptom index (RSI). Results: The mean age of the cohort was 35±06.51 (age range, 8-55). Mean RSI of all patients was 24.8 before treatment with combination of PPIs and H2 receptor antagonists. Significant change in RSI were observed after the first 8 weeks of therapy and no further significant changes were observed over the next 16 weeks. Mean RFS of the patients was 12 before starting the treatment and there was a significant response in mean RFS at 16 weeks of therapy.Conclusions: A surrogate high-dose prebreakfast PPI (40 mg pantoprazole) and a bedtime high-dose ranitidine (300 mg) dosing regimen is effective in improving RSI and RFS in majority of cases who present with LPR.

show abstract

Treating laryngopharyngeal reflux: Evaluation of an anti-reflux program with comparison to medications

Cited by 31 publications

References 32 publications

Treatment of laryngopharyngeal reflux disease: A systematic review

Treatment of laryngopharyngeal reflux disease: A systematic review

Possible Effects of Proton Pump Inhibitors on Hearing Loss Development

Combination drug therapy for laryngopharyngeal reflex

Contact Info

Product

Resources

About